|1.||Demidem, Aicha: 8 articles (01/2010 - 02/2003)|
|2.||Morvan, Daniel: 8 articles (01/2010 - 02/2003)|
|3.||Madelmont, Jean Claude: 4 articles (01/2008 - 02/2003)|
|4.||Stepien, Georges: 3 articles (01/2010 - 01/2009)|
|5.||Schwartz, Laurent: 2 articles (01/2010 - 01/2008)|
|6.||Guénin, Samuel: 2 articles (01/2009 - 01/2008)|
|7.||Thivat, Emilie: 2 articles (01/2009 - 01/2005)|
|8.||Merle, Patrick: 2 articles (01/2008 - 09/2006)|
|9.||Caillaud, Denis: 2 articles (01/2008 - 09/2006)|
|10.||Li, Lili: 1 article (01/2015)|
11/01/1997 - "These results provide evidence that MGMT expression influences both intrinsic and acquired colon tumor CENU resistance, that selective expansion of AGT+ colon tumor cells commonly occurs after CENU exposure, and that BG is effective in sensitizing colon tumors to CENUs, even when only a small fraction of the cells in a heterogeneous tumor express MGMT."
01/01/2009 - "The metabolic profile of MDS combined with CENU and ANOVA analysis revealed the implication of Met and phospholipid metabolism in the observed synergy, which may be interpreted as a Met-sparing metabolic reprogramming of tumors. "
09/01/2006 - "This article demonstrates the release by CENU-treated tumors of growth inhibitory differentiation-inducing soluble factors. "
09/01/1999 - "However, in addition to restoring CENU tumor cell sensitivity, 6-BG also increases the cytotoxic effects of CENUs on hematopoietic cells. "
09/01/1999 - "6-BG is being tested as an approach to treat CENU-resistant tumors that overexpress endogenous MGMT. "
|2.||Melanoma (Melanoma, Malignant)
09/01/2006 - "In a previous study, it was reported that secondary untreated melanoma tumors implanted several weeks after and at distance from primary chloroethylnitrosourea (CENU)-treated tumors underwent differentiation and growth inhibition. "
02/01/2003 - "Using these modalities we previously demonstrated that a mouse-bearing melanoma tumor responded to chloroethyl nitrosourea (CENU) treatment in vivo by altering its Plp metabolism. "
04/01/1998 - "Cystemustine (N'-(2-chloroethyl)-N-(2-(methylsulphonyl)ethyl)-N'-nitrosourea) is a new chloroethylnitrosourea (CENU) being used in phase II clinical trials of disseminated melanoma. "
01/01/2005 - "Fifty-three patients with metastatic melanoma were treated with Cystemustine, a chloroethyl nitrosourea (CENU) (60 or 90 mg/m2). "
12/01/1998 - "Cystemustine (N'-(2-chloroethyl)-N-(2-(methylsulphonyl)ethyl)-N'-nitrosourea), a new anticancer chloroethylnitrosourea (CENU) is being tested in a phase II clinical trial of disseminated melanoma. "
05/01/1999 - "We evaluated MGMT expression in 22 glioma specimens by using an immunofluorescence assay and compared the results with clinical responses of the patients to CENU-based chemotherapy. "
06/15/1998 - "The authors evaluated MGMT expression in 22 glioma specimens by using an immunofluorescence assay and compared the results with clinical response of the patients to CENU-based chemotherapy. "
10/01/1996 - "Thus, the low MGMT activity of gliomas may provide a theoretical basis for application of CENU chemotherapy."
11/01/1991 - "Six (38%) out of 17 glioma cases showed a value below 100 fmol/mg/hr and four cases (24%) a value below 60 fmol/mg/hr. These results provide a biological basis for applying CENU chemotherapy on glioma patients with a lower value of O6-AT enzyme."
02/01/2009 - "This study has investigated if individual DNA adducts formed in human glioma cells treated with (3)H-1-(2-chloroethyl)-1-nitrosourea ((3)H-CNU) could be used as molecular dosimeters of response after CENU treatment. "
01/01/2009 - "A model of B16 melanoma tumor in vivo was treated by MDS alone and in combination with chloroethylnitrosourea (CENU). "
01/01/2008 - "To obtain further information on the role of PP2A in tumors and response to DNA damage, we investigated the relationship between PP2A methylation and activity, cell proliferation, Akt activation, c-Myc expression and PTEN activity in B16 melanoma cells untreated and after chloroethylnitrosourea (CENU) treatment. "
09/01/2006 - "To see whether CENU-induced bystander effects were still effective on non-parental syngeneic secondary tumors, Lewis lung (3LL) secondary tumors were inoculated in recipients bearing CENU-treated B16 melanoma tumors. "
09/01/2006 - "We recently showed, using a parental double B16 melanoma tumor model that, in the presence of CENU-treated primary tumors, untreated secondary tumors exhibited growth inhibition. "
02/01/2003 - "The aims of the present study were to investigate whether HRMAS proton total correlation spectroscopy (TOCSY) could be used as a quantitative technique to probe Plp metabolism, and to determine the Plp metabolism response of cultured B16 melanoma cells to CENU treatment in vitro. "
|5.||Brain Neoplasms (Brain Tumor)
11/01/1999 - "In order to evaluate these approaches properly, we designed a syngenic rat brain-tumor model resistant to CENU. "
11/01/1999 - "Chloroethyl-nitrosourea (CENU) is one of the most potent chemotherapeutic agents for brain tumors. "
11/01/1989 - "We propose that such interactions between GSH and the CENUs may constitute an important aspect of CENU metabolism and provide a potential means by which brain tumor cells can circumvent CENU toxicity and exhibit resistance to this class of agents."
11/01/1992 - "Chloroethylnitrosourea (CENU) chemotherapy has yielded limited benefit on survival of malignant brain tumors. "
11/01/1991 - "We measured O6-AT activity in human brain tumors in order to obtain basic knowledge of whether or not CENU chemotherapy can be applied selectively on brain tumors. "
|1.||N'- (2- chloroethyl)- N- (2- (methylsulfonyl)ethyl)- N'- nitrosourea
|4.||DNA (Deoxyribonucleic Acid)
|7.||A-Form DNA (A-DNA)
|8.||Complementary DNA (cDNA)
|9.||Reactive Oxygen Species (Oxygen Radicals)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)